410 related articles for article (PubMed ID: 12646950)
1. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
Posey JA; Ng TC; Yang B; Khazaeli MB; Carpenter MD; Fox F; Needle M; Waksal H; LoBuglio AF
Clin Cancer Res; 2003 Apr; 9(4):1323-32. PubMed ID: 12684400
[TBL] [Abstract][Full Text] [Related]
3. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
Zhang H; Li Y; Li H; Bassi R; Jimenez X; Witte L; Bohlen P; Hicklin D; Zhu Z
Leuk Lymphoma; 2004 Sep; 45(9):1887-97. PubMed ID: 15223651
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
6. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
[TBL] [Abstract][Full Text] [Related]
8. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
Lu D; Shen J; Vil MD; Zhang H; Jimenez X; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2003 Oct; 278(44):43496-507. PubMed ID: 12917408
[TBL] [Abstract][Full Text] [Related]
9. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
Miao HQ; Hu K; Jimenez X; Navarro E; Zhang H; Lu D; Ludwig DL; Balderes P; Zhu Z
Biochem Biophys Res Commun; 2006 Jun; 345(1):438-45. PubMed ID: 16682007
[TBL] [Abstract][Full Text] [Related]
10. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.
Dias S; Hattori K; Zhu Z; Heissig B; Choy M; Lane W; Wu Y; Chadburn A; Hyjek E; Gill M; Hicklin DJ; Witte L; Moore MA; Rafii S
J Clin Invest; 2000 Aug; 106(4):511-21. PubMed ID: 10953026
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
14. [Effect of monoclonal antibody against extracellular domain III of vascular endothelial growth factor receptor KDR on proliferation of vascular endothelial cells].
Li R; Xiong DS; Shao XF; Xu YF; Zhu ZP; Yang CZ
Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):209-12. PubMed ID: 15949417
[TBL] [Abstract][Full Text] [Related]
15. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
16. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor as a marker of tumor endothelium.
Brekken RA; Huang X; King SW; Thorpe PE
Cancer Res; 1998 May; 58(9):1952-9. PubMed ID: 9581838
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]